A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Recruiting · NCT07552077 · Registry updated 2026-04-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU) | Neoplasms by Histologic Type, angiokeratoma, neoplasm, vascular cancer | Recruiting | Phase 2 | 2026-04-27 | NCT07552077 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Palvella Therapeutics, Inc. | 4 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleaver Medical Group | Dawsonville | United States | 1 |
| Epiphany Dermatology | Southlake | United States | 2 |
| Unified Health | Sherman Oaks | United States | 1 |
| Vividia Dermatology | Las Vegas | United States | 1 |